Navigation Links
QLT acquires leading edge ocular drug delivery system from ForSight Labs
Date:10/8/2007

s, the safety and effectiveness of the acquired technology, the timing, expense and uncertainty associated with the regulatory approval process for products, uncertainties regarding our future operating results, the general competitive condition in the biotechnology and drug delivery industry and general economic conditions, fluctuations in the real estate market and interest rates; and other risk factors which are described in detail in QLT's Annual Information Form on Form 10-K, quarterly reports on Form 10-Q, Registration Statement on Form S-4 and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are based on our current expectations and QLT does not assume any obligation to update such information to reflect later events or developments, except as may be required by law.

CONTACT: QLT Inc.: Vancouver, Canada, Therese Hayes, Telephone: (604) 707-7000 or (800) 663-5486, Fax: (604) 707-7001


'/>"/>
SOURCE QLT Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ossur Acquires the U.S. Orthopaedics Company
2. Stem of Hope: Stem Cell Research Acquires a Brittle Star As A model
3. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
4. Premier Army Hospital Acquires PET-CT Scanner
5. Wockhardt acquires Protinex, Farex brands from Netherland Co
6. Indoco Remedies Acquires La Nova Chem
7. Ranbaxy Acquires Glaxosmithklines Generic Unit in Spain
8. AIIMS Acquires Four-Armed Robot to Assist in Surgeries
9. Apollos Global Arm Acquires US-based Firm
10. ‘Obesity’ Acquires Permanent Resident Status in the US
11. Indias Wockhardt Acquires Irish Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... June 29, 2015 , ... ... series as part of its support program. This discussion series is part of ... other support services to those affected by mesothelioma. , The six week discussion ...
(Date:6/29/2015)... ... 2015 , ... The Society for Immunotherapy of Cancer (SITC) ... accelerated approval of Bristol-Myers Squibb’s Opdivo® (nivolumab) for the treatment of metastatic melanoma. ... nivolumab for patients with metastatic melanoma in Europe represents a major advance in ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... now being offered at NewYork-Presbyterian/Weill Cornell Medical Center. The device is the first ... an alternative to continuous positive airway pressure (CPAP), the current standard of care ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... , **FDAnews Webinar**, July 16, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... application of human factors engineering to the design of new products as well ...
(Date:6/29/2015)... York, NY (PRWEB) , ... June 29, 2015 ... ... Mount Sinai have developed a new approach to build nearly complete genomes by ... complex forms of genomic variation, critically important for their association with human disease, ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Provides Support for Patients and Families 2Health News:Mesothelioma Organization Provides Support for Patients and Families 3Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4
... Researchers comparing brain changes leading to dementia in people ... report initial results in a recent issue of Neurology.,// ... of all people with Down syndrome will eventually develop ... with Down syndrome show signs of the brain tangles ...
... significantly reduce the spread of the genital herpes virus.,Researchers ... one partner was diagnosed with //type 2 herpes and ... herpes causes a chronic genital viral infection and is ... given either 500 milligrams of valacyclovir once a day ...
... may do less harm than the X-rays used to diagnose the ... to have a significant effect on// how children with minor head ... of radiation can impair intellectual development. , ,The doses ... sometimes be done to check if there is any damage after ...
... twins, researchers conducted telephone interviews with 1,213 sets of ... to better understand the hereditary and environmental effects on ... but by interviewing the twins’ children (ages 12 to ... ,Although there is little question in the medical community ...
... suicide rates among more than 5 million service men and ... aimed at reducing an alarmingly high rate of suicide seen ... suicide rate had been particularly higher for black and white ... key components of the ongoing program are to provide support ...
... 20 percent to 30 percent of students are regularly ... as those attacked by bullies. In some cases, children ... and are victims of bullies. In all cases, these ... aren’t involved in bullying. However, most studies have relied ...
Cached Medicine News:Health News:Dementia and Down Syndrome 2Health News:Head injury X-rays may actually be causing harm, 2
(Date:6/29/2015)... Calif. , June 29, 2015 /PRNewswire/ ... of advanced visual prosthetic devices for the ... announced the publication of "Long-Term (60-month) Results ... Safety Outcomes Stratified by Age in Patients ... Clinical Ophthalmology . The 5-year data show ...
(Date:6/29/2015)... 29, 2015 /PRNewswire/-- CytRx Corporation (NASDAQ: CYTR ), ... today announced the presentation of interim results from its ... and safety of aldoxorubicin for the treatment of Kaposi,s ... presented on Wednesday, July 1, 2015 during a poster ... Herpesvirus (KSHV) and Related Agents in Hollywood, ...
(Date:6/29/2015)... , June 29, 2015  The automotive ... features to cars on the basis of consumer ... industry is now on the verge of integrating ... While automotive HWW non-critical features such as reconfigurable ... present in 30 to 40 percent of all ...
Breaking Medicine Technology:Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 2Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 3Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 4Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 5CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 2CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 3CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 4CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 5CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 6Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Ouchless ® Needle by BellaNovus Development Company ... Dr. Mariano Busso is the latest in a growing ... its use for cosmetic injections. Dr. Busso is on ... localized pain resulting from cosmetic injections. Ouchless ® ...
... a critical care company focused on developing and commercializing ... the U.S. Food and Drug Administration (FDA) has granted ... oxide (iNO) with the INOpulse® DS drug-delivery system as ... investigational new drug application (IND) for PAH was submitted ...
Cached Medicine Technology:New Ouchless® Needle Collection Announces Leading Dermatology Testimonial 2FDA Grants Orphan Drug Designation to Ikaria® For Use of Inhaled Nitric Oxide in Pulmonary Arterial Hypertension 2FDA Grants Orphan Drug Designation to Ikaria® For Use of Inhaled Nitric Oxide in Pulmonary Arterial Hypertension 3FDA Grants Orphan Drug Designation to Ikaria® For Use of Inhaled Nitric Oxide in Pulmonary Arterial Hypertension 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: